October 3rd 2025
Alto Neuroscience's ALTO-101 gains FDA Fast Track designation, promising a novel treatment for cognitive impairment in schizophrenia.
Metabolic Monitoring of Antipsychotic Medications: What Psychiatrists Need to Know
May 29th 2017Because patients who have psychiatric illnesses typically receive less frequent medical care, psychiatrists must aim to ensure appropriate monitoring of metabolic parameters when antipsychotic medications are used.
Read More
A First-Episode Psychosis Treatment Program: “The Disease Doesn’t Define Me”
February 28th 2017The Psychiatric Transition Program at the Naval Medical Center in San Diego is a specialized first-episode psychosis program that provides coordinated specialty care to active-duty service members with serious mental illness.
Read More